Fermenta Biotech lists on NSE, readies Vitadee Green ramp-up
Fermenta Biotech has added an NSE listing while retaining its BSE presence. The company plans to ramp up production of its FSSAI-approved plant-source Vitamin D3, Vitadee Green, over the next three months for food, nutraceutical and health-supplement markets in India and overseas.
What happened
Fermenta Biotech listed on NSE while retaining its BSE listing. Its FSSAI-approved plant-source Vitamin D3, Vitadee Green, will be ramped up over three months
Key facts
- 2,94,30,987 equity shares
- ₹5 face value
- 75 years
- customers in more than 60 countries
- Founded in 1951
- BSE-listed since 1977
- 2017-18 reverse merger
- ramp-up over the next three months
- Vitamin D sales account for over 70% of revenue
- ₹551 crore revenue
- year ended March 2026
Why this matters
Strategic buyers and partners should assess Fermenta as a potential plant-based micronutrient collaborator, particularly for clean-label formulations and international ingredient distribution.
What to watch
- First disclosed commercial orders, customer names or repeat-order evidence for Vitadee Green.
- Evidence that the three-month production ramp meets planned capacity, yield and quality targets.
- Gross-margin commentary showing whether plant-based D3 earns a premium over Fermenta's legacy Vitamin D portfolio.
- New FSSAI-compliant fortified-food launches using vegan Vitamin D3.
- Export registrations, distributor appointments, certifications and international customer qualification wins.
- NSE trading liquidity, institutional ownership changes and any capital-raising activity tied to capacity expansion.
- Secure anchor purchase orders or multi-quarter supply agreements with Indian nutraceutical and fortified-food brands.
- Publish product specifications, stability data, dosage formats and comparative pricing versus animal-derived Vitamin D3.
- Expand distributor coverage in export markets with high vegan supplement penetration.
- Use the NSE listing to improve institutional outreach, liquidity and credibility with larger B2B procurement teams.
- Prioritize scalable premix and ready-to-formulate partnerships that shorten customer development cycles.